Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Short Interest Up 755.8% in October

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,203,300 shares, an increase of 755.8% from the September 30th total of 140,600 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Sino Biopharmaceutical Stock Performance

Shares of SBMFF remained flat at $0.47 during midday trading on Friday. Sino Biopharmaceutical has a fifty-two week low of $0.31 and a fifty-two week high of $0.49. The stock has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.37.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.